COVID-19.рф: ИНФОРМАЦИЯ ПРОТИВ ПАНДЕМИИ

Поиск по репозиторию

Статья

Regional advisory board position statement on optimal pneumococcal vaccination in adults update to 2011 consensus on adult pneumococcal disease: Update on optimal pneumococcal vaccination in adults

E. Ludwig, S. Ünal, M. Bogdan, R. Chlíbek, Y. Ivanov, R. Kozlov, H. Lode, Z. Mészner, R. Prymula, G. Rahav, A. Skoczyńska, I. Solovič, A. Sayiner,
2021
https://doi.org/10.21101/cejph.a3959

Background: An important development in the field of adult pneumococcal vaccination since the last Consensus Statement, published by the Expert Panel of Central and Eastern Europe and Israel (the Region) in September 2012, was the licensure of the 13-valent pneumococcal conjugate vaccine (PCV13) for adults aged 50 years and older. Discussion: The Expert Panel has developed this Position Statement as an update to its previous Consensus to address the following topics which are likely to be on the agenda of national scientific societies during the ongoing updates of vaccination recommendations in the Region: the availability of a pneumococcal conjugate vaccine for adults over 50 years of age, the available clinical evidence on its use in adults, and the future place of conjugate vaccines in adult pneumococcal vaccination. The Expert Panel concluded that there is sufficient epidemiologic immunogenicity and safety evidence to use PCV 13 in adults over 50 years of age. Results: The use of conjugate vaccine induces immunological memory and can overcome some limitations associated with the plain polysaccharide vaccine (PPV). It was also agreed that, if the use of PPV is considered appropriate, PCV13 should be administered first, regardless of prior pneumococcal vaccination status.

Цитирование

Похожие публикации

A WAO — ARIA — GA<sup>2</sup>LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020
I. Ansotegui, G. Melioli, G. Canonica,
Toward a geriatric approach to patients with advanced age and cardiovascular diseases: position statement of the EuGMS Special Interest Group on Cardiovascular Medicine
A. Ungar, G. Rivasi, M. Petrovic,
Согласованная экспертная позиция по диагностике и лечению фульминантного миокардита в условиях пандемии COVID-19
Ойноткинова О. Ш., Масленникова О. М., Ларина В. Н.,

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • E. Ludwig
    Division of Infectious Diseases, Department of Internal Medicine No II, Semmelweis Medical University, Budapest, Hungary
  • S. Ünal
    Section of Infectious Diseases, Department of Internal Medicine, Hacettepe University, Ankara, Turkey
  • M. Bogdan
    Carol Davila University of Medicine, Bucharest and Marius Nasta Institute of Pneumophthisiology, Bucharest, Romania
  • R. Chlíbek
    Department of Epidemiology, University of Defence, Hradec Králové, Czech Republic
  • Y. Ivanov
    Pulmonology and Phthisiatry Clinic, University Hospital, Pleven, Bulgaria
  • R. Kozlov
    Institute of Antimicrobial Chemotherapy, Smolensk State Medical Academy, Smolensk, Russian Federation
  • H. Lode
    Research Center of Medical Studies (RCMS), Institute for Clinical Pharmacology, Charité University Medicine of Berlin, Berlin, Germany
  • Z. Mészner
    National Institute of Child Health, Szent Laszlo Hospital for Infectious Diseases, Budapest, Hungary
  • R. Prymula
    University Hospital, Hradec Králové, Czech Republic
  • G. Rahav
    Infectious Disease Unit, Sheba Medical Centre, Tel Hashomer, Ramat-Gan, Israel
  • A. Skoczyńska
    National Reference Centre for Bacterial Meningitis, Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Warsaw, Poland
  • I. Solovič
    Pulmonology Department of National Institute for TB, Lung Diseases and Thoracic Surgery, Vyšné Hágy, Catholic University, Ružomberok, Slovakia
  • A. Sayiner
    Department of Chest Diseases, Ege University, Izmir, Turkey
Название журнала
  • Central European Journal of Public Health
Том
  • 21
Выпуск
  • 4
Страницы
  • 233-236
Ключевые слова
  • Pneumococcus vaccine; prevenar13; article; Europe; human; immunology; Israel; middle aged; pneumococcal infection; practice guideline; Europe; Humans; Israel; Middle Aged; Pneumococcal Infections; Pneumococcal Vaccines; Practice Guidelines as Topic
Издатель
  • Czech National Institute of Public Health
Тип документа
  • journal article
Источник
  • scopus
COVID-19.рф: Информация против пандемии

Адрес: 115114, Москва, ул. Летниковская, д. 4, стр.5, офис 2.4
тел.\факс: +7(499)754-99-94, доб. 502
e-mail: covid19@neicon.ru

Проект реализуется с использованием гранта Президента Российской Федерации на развитие гражданского общества, предоставленного Фондом президентских грантов.

Содержимое сайта, если не указано иное, опубликовано в соответствии с лицензией Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная (CC BY 4.0). Права на материалы, переданные партнерами проекта, принадлежат их правообладателям.

© 2025 NEICON